Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT01355120Phase 2Completed

THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease

Role: lead

NCT02523313Phase 2Completed

Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

Role: lead

NCT02196961Phase 2Completed

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation

Role: lead

NCT02902042Phase 1Completed

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Role: lead

NCT02410863Phase 2Terminated

Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma

Role: lead

NCT02308553Phase 1Completed

Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma

Role: lead

All 6 trials loaded